Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to “Hold” at Jefferies Financial Group

Jefferies Financial Group downgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research note published on Monday, MarketBeat.com reports. They currently have $1.00 price objective on the stock.

Several other research firms have also recently weighed in on EYPT. Guggenheim reaffirmed a “buy” rating and set a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday, August 17th. Citigroup cut their target price on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Finally, Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $21.85.

Eyepoint Pharmaceuticals Trading Up 6.1%

Shares of NASDAQ EYPT opened at $0.43 on Monday. The firm has a market cap of $37.07 million, a PE ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1-year low of $0.39 and a 1-year high of $19.11. The company has a fifty day moving average price of $4.25 and a 200 day moving average price of $10.12.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The firm had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Equities research analysts forecast that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Commodore Capital LP acquired a new stake in Eyepoint Pharmaceuticals in the 1st quarter valued at $36,414,000. Hsbc Holdings PLC bought a new stake in Eyepoint Pharmaceuticals during the 1st quarter worth about $10,743,000. Janus Henderson Group PLC lifted its position in Eyepoint Pharmaceuticals by 22.6% during the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after buying an additional 663,439 shares in the last quarter. Stempoint Capital LP boosted its stake in shares of Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after buying an additional 456,915 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth about $3,869,000. Institutional investors own 99.41% of the company’s stock.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Traders purchased a large volume of EYPT call options, signaling increased speculative interest and expectations that the stock could rebound or move sharply higher. Stock Traders Purchase Large Volume of Call Options on Eyepoint Pharmaceuticals
• Positive Sentiment: RBC identified the company’s upcoming diabetic macular edema (DME) study readout as a potential catalyst. Positive data could help offset the recent failure of an EyePoint wet age-related macular degeneration (wAMD) trial to meet its endpoint. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint
• Neutral Sentiment: Analyst sentiment remains mixed across EyePoint and other healthcare companies, reflecting uncertainty over the company’s clinical pipeline and future catalysts. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: Laidlaw reaffirmed its “hold” rating. RBC also maintained a “sector perform” view while cutting its price target to $1.00, and Mizuho reaffirmed “neutral” with a $0.50 target. These targets remain above the recent share price but indicate limited conviction.
• Negative Sentiment: Jefferies Financial Group lowered its rating on EyePoint, adding to pressure from a more cautious analyst outlook. Eyepoint Pharmaceuticals Stock Rating Lowered by Jefferies
• Negative Sentiment: Guggenheim also downgraded the stock, reinforcing concerns after the wAMD trial miss and highlighting the high-risk nature of EyePoint’s development program. Eyepoint Pharmaceuticals Stock Gets Downgrade from Guggenheim

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.